If they came out with this I would assume this is a good sign as we all thought they would be belly up at end of month
QUICK LINKS :
Goldman Sachs Conviction Buy List
Carl Icahn News
Warren Buffett News
Get it on Google Play
Form DEF 14A BG Medicine, Inc. For: Aug 05
Stock Quotes (1)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2016
Wall St. opens higher for fourth straight day
BlackBerry (BBRY) Tops Q1 EPS by 8c; Guides for Narrower-than-Expected Loss in FY17
Sterling hits 2016 high on bets Britain will stay in EU
5 Key Things Analysts are Saying About Red Hat (RHT) Following Earnings
Pre-Open Stock Movers 06/23: (OGEN) (OCN) (APOG) Higher; (SCS) (RHT) (BBBY) Lower (more...)
June 23, 2016 8:16 AM EDT
Tweet Share E-mail
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant x Filed by a Party other than the Registrant ¨
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Under Rule 14a-12
BG MEDICINE, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x No fee required.
¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
Proposed maximum aggregate value of transaction:
Total fee paid:
¨ Fee paid previously with preliminary materials.
¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:
Amount previously paid:
Form, Schedule or Registration Statement No:
Table of Contents
June 23, 2016
To Our Stockholders:
You are cordially invited to attend the 2016 annual meeting of stockholders of BG Medicine, Inc. (the “Company” or “BG Medicine”) to be held at 11:00 a.m. ET on August 5, 2016 at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111.
Details regarding the meeting, the business to be conducted at the meeting, and information about BG Medicine, Inc. that you should consider when you vote your shares are described in this proxy statement.
At the annual meeting, one person will be elected to our Board of Directors. In addition, we will ask stockholders to ratify the selection of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016 and to approve the compensation of our named executive officers, as disclosed in this proxy statement. The Board of Directors recommends the approval of each of these proposals. Such other business will be transacted as may properly come before the annual meeting.
We hope you will be able to attend the annual meeting. Whether you plan to attend the annual meeting or not, it is important that you cast your vote either in person or by proxy. You may vote over the Internet, by telephone or by mail. When you have finished reading this proxy statement, you are urged to vote in accordance with the instructions set forth in this proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend.
Thank you for your continued support of BG Medicine, Inc. We look forward to seeing you at the annual meeting.
Paul R. Sohmer, M.D.
President and Chief Executive Officer
Medical Device Sales Representative Jobs in Pittsburgh, PA | Glassdoor
glassdoor › Jobs › Medical Device Sales Representative
1 day ago - join the BG Medical Sales Team: You can land a CAREER (not just a job!) … in the prestigious Medical Device Sales Arena! You… TOP-TEN B2B SALES ...
You visited this page on 6/21/16.
I don't know if I would go to that cardiologist. Do they not read and keep up to date? Good grief I would want my doc to know all the options and be well informed.
As for the one Abt rep - how long have they been a rep? Do they actually hit their sales numbers? Also sales people don't know how to sell everything usually most have narrow tunnel vision and get stuck in a rut on one product.
There are lots of variables there.
If some kind of news came out.... There are daily new articles on Galectin-3 - Just can't see why this company chooses to be so quiet. At least a report of what they are actually working on to justify their salary's. Do they even work? Are they calling trying to build interest? What are they doing?
Just thought I would post since it has been a week from last posting.
LOL some of us keep checking for info.......Only to be disappointed nothing has happened - Surely only 3 more months and we shall know what is going on BK - or small profitability
It sure would be nice if you could just post link: Do a search it was on medscape at the bottom it mentions BGMD and most of the test partners we have been talking about.
CHICAGO, IL — Patients experiencing a first type 2 MI (T2MI), related to supply-demand inequity, rather than classical plaque rupture, have similar or worse prognosis than those with incident type 1 MI (T1MI), new research suggests.
The Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study prospectively enrolled 1251 patients undergoing coronary or peripheral angiography. Over a median 3.4 years of follow-up, it found that T2MI patients had a higher rate of subsequent major adverse cardiovascular events (MACE) than those without T2MI (100 vs 17.6 events per 100 person-years; P
Although the microplate version of the BGM Galectin-3 test is the primary, current focus of our commercialization strategy, we have partnered with four leading diagnostic instrument manufacturers to develop automated versions of our galectin-3 test, which we expect will result in broader customer acceptance and clinical adoption of our galectin-3 test. To execute this element of our commercialization strategy, we have entered into worldwide license, development and commercialization agreements with Abbott Laboratories, or Abbott, Alere Inc., or Alere, bioMérieux SA, or bioMérieux, and Siemens Healthcare Diagnostics Inc., or Siemens, for the development of our galectin-3 test on their automated instruments, including point-of-care instruments, which are utilized within hospitals and other medical organizations. We believe that through these four partners we will have broad access to major segments of the diagnostics market, including hospital laboratories, private laboratories, reference laboratories and physician office laboratories, due to the widespread coverage of our partners’ installed bases. Under the agreements, our partners are responsible for developing and commercializing the tests and we are responsible for furthering clinical awareness and developing the market for galectin-3 testing. (Says Worldwide not sure with which one)
I agree and if you cut that then the company is profitable. I would like to know what they have been doing to deserve any of it.
Well looking at the numbers - there shouldn't be any research cost this quarter or marketing expense since Abbot is handling. Taking this into consideration the numbers aren't that bad and are pretty close. Just a few more sales they should be profitable. Am I off track in my thinking?
Thanks for posting...... It is going to be a bumpy ride - hopefully the wheels stay on the bus and we all make money.....
No it talked about sales and how they received first payment from abbot. I would copy and paste but not reading back through it to find it right now :-)